BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Favalli EG, Matucci-Cerinic M, Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev 2020;19:102421. [PMID: 31733368 DOI: 10.1016/j.autrev.2019.102421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Giollo A, Fuzzi E, Doria A. Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding? Autoimmun Rev 2022;21:103031. [PMID: 34995761 DOI: 10.1016/j.autrev.2022.103031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Abi-ghaida F. The serendipitous integration of small boron-embedded molecules into medicinal chemistry. Fundamentals and Applications of Boron Chemistry 2022. [DOI: 10.1016/b978-0-12-822127-3.00006-5] [Reference Citation Analysis]
3 Hysa E, Gotelli E, Sammorì S, Cimmino MA, Paolino S, Pizzorni C, Sulli A, Smith V, Cutolo M. Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review. Autoimmun Rev 2021;:102995. [PMID: 34798314 DOI: 10.1016/j.autrev.2021.102995] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
4 Roszkowski L, Ciechomska M. Tuning Monocytes and Macrophages for Personalized Therapy and Diagnostic Challenge in Rheumatoid Arthritis. Cells 2021;10:1860. [PMID: 34440629 DOI: 10.3390/cells10081860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Raimondo MG, Biggioggero M, Coletto LA, Ramming A, Caporali R, Favalli EG. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. Expert Rev Clin Pharmacol 2021;14:661-70. [PMID: 33847204 DOI: 10.1080/17512433.2021.1913050] [Reference Citation Analysis]
6 Galozzi P, Bindoli S, Doria A, Sfriso P. The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmun Rev 2021;20:102785. [PMID: 33621698 DOI: 10.1016/j.autrev.2021.102785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
7 Wu R, Li N, Zhao X, Ding T, Xue H, Gao C, Li X, Wang C. Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. Autoimmun Rev 2020;19:102645. [PMID: 32801037 DOI: 10.1016/j.autrev.2020.102645] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
8 Massalska M, Maslinski W, Ciechomska M. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells 2020;9:E1876. [PMID: 32796683 DOI: 10.3390/cells9081876] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
9 Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. Autoimmunity Reviews 2020;19:102509. [DOI: 10.1016/j.autrev.2020.102509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19:102523. [PMID: 32205186 DOI: 10.1016/j.autrev.2020.102523] [Cited by in Crossref: 264] [Cited by in F6Publishing: 221] [Article Influence: 132.0] [Reference Citation Analysis]
11 Zhang Y, Ji T, Ma S, Wu W. MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region. Int Immunopharmacol 2020;82:106220. [PMID: 32151962 DOI: 10.1016/j.intimp.2020.106220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]